» Articles » PMID: 38280134

Clinical Importance of Serum MiRNA Levels in Breast Cancer Patients

Overview
Journal Discov Oncol
Publisher Springer
Specialty Oncology
Date 2024 Jan 27
PMID 38280134
Authors
Affiliations
Soon will be listed here.
Abstract

There is limited data on the relationship of miRNAs with parameters that may affect surgical management or reflect tumour prognosis. It was aimed to evaluate serum miRNA levels in breast carcinoma cases and reveal the relationship between these levels and prognosis-related factors such as the histological type of the tumour, estrogen receptor, progesterone receptor, Ki-67 index, HER-2neu, E-cadherin, tumour size, CK5/6, CA15.3 levels, number of tumour foci, number of metastatic lymph nodes, and status of receiving neoadjuvant therapy. Thirty-five patients with a histopathologically confirmed breast carcinoma diagnosis in the case group and 35 healthy individuals in the control group were examined. miR-206, miR-17-5p, miR-125a, miR-125b, miR-200a, Let-7a, miR-34a, miR-31, miR-21, miR-155, miR-10b, miR-373, miR-520c, miR-210, miR-145, miR-139-5p, miR-195, miR-99a, miR-497 and miR-205 expression levels in the serum of participants were determined using the Polymerase Chain Reaction method. While serum miR-125b and Let-7a expression levels were significantly higher in breast cancer patients, miR-17-5p, miR-125a, miR-200a, miR-34a, miR-21, miR-99a and miR-497 levels were significantly lower in them. The Let-7a expression level had a statistically significant relationship with breast cancer histological type and HER-2neu parameters, miR-17-5p, miR-125b, Let-7a, miR-34a, miR-21 and miR-99a levels with E-cadherin, miR-34a, miR-99a and miR-497 with CA15.3, miR-125b, miR-200a and miR-34a with the number of metastatic lymph nodes, miR-125a with the number of tumour foci and miR-200a with the status of having the neoadjuvant therapy. Serum miR-17-5p, miR-125a, miR-125b, miR-200a, Let-7a, miR-34a, miR-21, miR-99a and miR-497 expression levels were determined to have predictive and prognostic importance in breast cancer.

Citing Articles

Integrated miRNA Signatures: Advancing Breast Cancer Diagnosis and Prognosis.

Samara M, Thodou E, Patoulioti M, Poultsidi A, Thomopoulou G, Giakountis A Biomolecules. 2024; 14(11).

PMID: 39595529 PMC: 11591846. DOI: 10.3390/biom14111352.


The Overexpressed MicroRNAs miRs-182, 155, 493, 454, and U6 snRNA and Underexpressed let-7c, miR-328, and miR-451a as Potential Biomarkers in Invasive Breast Cancer and Their Clinicopathological Significance.

Zavesky L, Jandakova E, Weinberger V, Minar L, Kohoutova M, Tefr Faridova A Oncology. 2024; 103(2):112-127.

PMID: 39134012 PMC: 11793102. DOI: 10.1159/000540863.


Impact of Long-Lasting Environmental Factors on Regulation Mediated by the miR-34 Family.

Stefanik P, Morova M, Herichova I Biomedicines. 2024; 12(2).

PMID: 38398026 PMC: 10887245. DOI: 10.3390/biomedicines12020424.

References
1.
Li Y, Kowdley K . Method for microRNA isolation from clinical serum samples. Anal Biochem. 2012; 431(1):69-75. PMC: 3481852. DOI: 10.1016/j.ab.2012.09.007. View

2.
Hu Y, Zhu Q, Tang L . MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. PLoS One. 2014; 9(3):e92099. PMC: 3956864. DOI: 10.1371/journal.pone.0092099. View

3.
Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z . Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One. 2012; 7(4):e34210. PMC: 3327688. DOI: 10.1371/journal.pone.0034210. View

4.
Eades G, Yang M, Yao Y, Zhang Y, Zhou Q . miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J Biol Chem. 2011; 286(47):40725-33. PMC: 3220489. DOI: 10.1074/jbc.M111.275495. View

5.
Tang Y, Zhou X, Ji J, Chen L, Cao J, Luo J . High expression levels of miR-21 and miR-210 predict unfavorable survival in breast cancer: a systemic review and meta-analysis. Int J Biol Markers. 2015; 30(4):e347-58. DOI: 10.5301/jbm.5000160. View